Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum
- 1 February 2018
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 73 (2) , 153-155
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial CancerEuropean Urology, 2018
- Immune Checkpoint Inhibition in Metastatic Urothelial CancerEuropean Urology, 2017
- Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 studyAnnals of Oncology, 2017
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial CarcinomaNew England Journal of Medicine, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.Journal of Clinical Oncology, 2017
- Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death ( PD )‐1 or PD ligand 1 inhibitor therapyBJU International, 2016
- Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial CarcinomaClinical Genitourinary Cancer, 2014
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009